

# I-Mab BioPharma (IMAB US)

## Lemzoparlimab showed encouraging data on MDS

I-Mab recorded RMB88.0mn revenue in 2021, mainly from licensing and collaboration revenue from AbbVie and CSPC. R&D expenses were RMB1.2bn in 2021 as compared to RMB984.7mn in 2020. Administrative expenses were RMB899.9mn (+123% YoY), primarily due to the team expansion for the preparation of product commercialization. Net loss in 2021 was RMB2.3bn (including RMB621.9mn share-based compensation expense). I-Mab had a strong cash position of RMB4.3bn as of end-2021. Considering upcoming milestone payments and potential out-license opportunities, I-Mab has sufficient cash balance to support future R&D activities.

- Encouraging results of lemzoparlimab (CD47) for 1L MDS.** In a phase 2 trial (NCT04202003), 70+ patients with newly diagnosed MDS or AML have been dosed with lemzoparlimab at 30 mg/kg in combo with AZA. An interim analysis of 22 MDS patients who had a median treatment duration  $\geq$  4months demonstrated encouraging preliminary results with ORR and CR rates comparable to that of magrolimab. In a previous study, magrolimab recorded 91% ORR and 42% CR in 33 MDS patients ([link](#)). I-Mab expects to present the detailed results in 2H22. With comparable efficacy to magrolimab and better safety profile, we expect lemzoparlimab to become an FIC & BIC CD47 antibody. I-Mab is planning to start a registrational trial in MDS this year.
- Multiple assets to be ready for commercialization in the next three years.** For the 7 assets in phase 2/3 trials, I-Mab expects to complete three near-term BLA filings and product launches during 2023-2025 in China, including felzartamab (CD38), eftansomatropin alfa (long-acting growth hormone), and potentially lemzoparlimab (CD47). With a new local manufacturing plan for felzartamab, I-Mab aims to file NDA for felzartamab for treatment of 3L MM in 2022. Additionally, the Company is in negotiation to in-license a pre-BLA product in the hematologic malignancy space, aiming to further expand its hematologic product portfolio. As for the manufacturing facilities, the Phase One facility with 6,000L capacity in Hangzhou will become operational in around Jun 2022, and the construction of the Phase Two facility (32,000L) may be completed by 2024.
- Uliledlimab (CD73) to release key results in mid-2022.** A phase 2 basket trial of uliledlimab (CD73) in combo with toripalimab (NCT04322006) in solid tumor patients is ongoing in China. I-Mab expects to release the preliminary data from this study at the 2022 ASCO meeting, which could be a catalyst for the license-out deal of uliledlimab.
- Maintain BUY.** To alleviate the US delisting risks, I-Mab has accelerated its listing process in HKEx, and plans to hire an accounting firm subject to inspection by the PCAOB to perform the audit from 2022. We maintain our DCF-based TP unchanged at US\$103.60 (WACC: 9.4%, terminal growth rate: 4.0%).

### Earnings Summary

(YE 31 Dec)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue (RMB mn)	1,543	88	794	1,270	2,040
Net profit (RMB mn)	471	(2,332)	(1,198)	(774)	(187)
EPS (RMB per ADS)	8.07	(30.69)	(14.99)	(9.68)	(2.34)
Consensus EPS (RMB per ADS)	N/A	N/A	(8.91)	(9.00)	(8.94)
R&D expenses (RMB mn)	(985)	(1,213)	(1,000)	(1,000)	(1,000)
Admin expenses (RMB mn)	(402)	(900)	(700)	(735)	(772)
Capex (RMB mn)	(8)	(100)	(100)	(100)	(100)

Source: Company data, Bloomberg, CMBIGM estimates

**BUY (Maintain)**

**Target Price** US\$103.60  
 (Previous TP US\$103.60)  
**Up/Downside** +446.70%  
**Current Price** US\$18.95

### China Healthcare Sector

#### Jill Wu, CFA

(852) 3900 0842

jillwu@cmbi.com.hk

#### Andy Wang

(852) 3657 6288

andywang@cmbi.com.hk

Mkt. Cap. (US\$ mn)	1,515
Avg. 3mths t/o (US\$ mn)	22.01
52W High/Low (US\$)	85.40/12.00
Total Issued Shares (mn)	80

Source: Bloomberg

### Shareholding Structure

Hillhouse Capital	8.99%
GIC	5.89%
Tasly Pharma	5.44%
Founder	5.40%
Genexine	4.62%
Rowe Price	4.17%
Others	65.49%


Source: Bloomberg, Wind

### Share performance

	Absolute	Relative
1-mth	-23.3%	-27.0%
3-mth	-60.4%	-56.9%
6-mth	-73.9%	-73.8%

Source: Bloomberg

### 12-mth price performance



Source: Bloomberg

### Auditor: PWC

Web-site: [www.i-mabbiopharma.com](http://www.i-mabbiopharma.com)

### Related report:

- A significantly undervalued biotech company with solid pipeline assets – 26 Jan 2022
- Appointment of a globally renowned oncologist to lead the R&D organization – 22 Dec 2021
- Strategic cooperation with Jumpcan accelerates commercialization for long-acting rhGH – 30 Nov 2021

Figure 1: Risk-adjusted DCF valuation

DCF Valuation (in RMB mn)	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E
EBIT	(1,198)	(774)	(187)	1,443	2,349	3,717	4,349	5,078	5,688	6,608	6,758	7,158	7,210	7,616
Tax rate	0%	0%	0%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%
EBIT*(1-tax rate)	(1,198)	(774)	(187)	1,227	1,997	3,159	3,696	4,316	4,835	5,617	5,744	6,084	6,128	6,474
+ D&A	34	49	61	70	77	82	86	89	92	94	95	96	97	98
- Change in working capital	(533)	(35)	(102)	(796)	(375)	(311)	(256)	(189)	(156)	(142)	(122)	(106)	(91)	(27)
- Capex	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(100)
<b>FCFF</b>	<b>(1,797)</b>	<b>(860)</b>	<b>(328)</b>	<b>401</b>	<b>1,599</b>	<b>2,831</b>	<b>3,426</b>	<b>4,116</b>	<b>4,671</b>	<b>5,469</b>	<b>5,618</b>	<b>5,974</b>	<b>6,035</b>	<b>6,445</b>
<b>Terminal value</b>														122,997
<b>FCF + Terminal value</b>	<b>(1,797)</b>	<b>(860)</b>	<b>(328)</b>	<b>401</b>	<b>1,599</b>	<b>2,831</b>	<b>3,426</b>	<b>4,116</b>	<b>4,671</b>	<b>5,469</b>	<b>5,618</b>	<b>5,974</b>	<b>6,035</b>	<b>129,442</b>
PV of enterprise (RMB mn)	50,978													
Net debt (RMB mn)	(1,645)													
Equity value (RMB mn)	52,622													
Equity value (US\$ mn)	8,280													
No. of ADS	79,924,675													
<b>DCF per share (US\$)</b>	<b>103.60</b>													
<b>Terminal growth rate</b>	<b>4.0%</b>													
<b>WACC</b>	<b>9.4%</b>													
Cost of Equity	12.0%													
Cost of Debt	4.0%													
Equity Beta	0.86													
Risk Free Rate	3.0%													
Market Risk Premium	10.5%													
Target Debt to Asset ratio	30.0%													
Effective Corporate Tax Rate	15.0%													

Source: CMBIGM estimates

Figure 2: Sensitivity analysis (US\$)

		WACC				
		8.4%	8.9%	9.4%	9.9%	10.4%
Terminal growth rate	5.0%	162.66	138.45	119.78	104.97	92.95
	4.5%	146.44	126.61	110.88	98.12	87.58
	4.0%	133.86	117.15	103.60	92.42	83.04
	3.5%	123.82	109.43	97.55	87.60	79.15
	3.0%	115.63	103.01	92.44	83.47	75.78

Source: Company data, CMBIGM estimates

Figure 3: CMBIGM estimates vs consensus

RMB mn	CMBIGM			Consensus			Diff (%)		
	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Revenue	794	1,270	2,040	923	1,018	1,717	-13.94%	24.68%	18.83%
Gross Profit	794	1,247	1,961	891	931	1,509	-10.82%	34.02%	29.94%
Operating Profit	(1,206)	(775)	(185)	(1,071)	(1,088)	(997)	N/A	N/A	N/A
Net profit	(1,198)	(774)	(187)	(967)	(1,125)	(1,128)	N/A	N/A	N/A
EPS (RMB)	(14.99)	(9.68)	(2.34)	(8.91)	(9.00)	(8.94)	N/A	N/A	N/A
Gross Margin	100.00%	98.25%	96.12%	96.50%	91.41%	87.91%	+3.50 ppt	+6.85 ppt	+8.22 ppt

Source: Company data, Bloomberg, CMBIGM estimates

## Financial Statements

### Income statement

YE Dec 31 (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E
<b>Revenue</b>	<b>1,543</b>	<b>88</b>	<b>794</b>	<b>1,270</b>	<b>2,040</b>
Cost of sales	0	(46)	0	(22)	(79)
<b>Gross profit</b>	<b>1,543</b>	<b>42</b>	<b>794</b>	<b>1,247</b>	<b>1,961</b>
Administrative expenses	(402)	(900)	(700)	(735)	(772)
R&D expenses	(985)	(1,213)	(1,000)	(1,000)	(1,000)
Selling expenses	0	0	0	(87)	(274)
Other gains/losses	304	(285)	(300)	(200)	(100)
<b>Operating profit</b>	<b>460</b>	<b>(2,356)</b>	<b>(1,206)</b>	<b>(775)</b>	<b>(185)</b>
Finance costs, net	23	21	8	1	(2)
<b>Pre-tax profit</b>	<b>483</b>	<b>(2,335)</b>	<b>(1,198)</b>	<b>(774)</b>	<b>(187)</b>
Income tax	(12)	3	0	0	0
Minority interests and others	0	0	0	0	0
<b>Attributable net profit (Net loss)</b>	<b>471</b>	<b>(2,332)</b>	<b>(1,198)</b>	<b>(774)</b>	<b>(187)</b>

### Cash flow summary

YE 31 Dec (RMB mn)	FY20A	FY21E	FY22E	FY23E	FY24E
<b>Profit before tax</b>	<b>471</b>	<b>(2,335)</b>	<b>(1,198)</b>	<b>(774)</b>	<b>(187)</b>
Depreciation and amortization, etc.	22	14	34	49	61
Change in working capital	(241)	328	(533)	(35)	(102)
Tax paid	0	3	0	0	0
Others	182	976	0	0	0
<b>Net cash from operating activities</b>	<b>434</b>	<b>(1,014)</b>	<b>(1,697)</b>	<b>(760)</b>	<b>(228)</b>
Capex	(8)	(100)	(100)	(100)	(100)
Net proceeds from disposal of short-term investments	12	0	0	0	0
Other investing activities	(206)	0	0	0	0
<b>Net cash from investing activities</b>	<b>(202)</b>	<b>(100)</b>	<b>(100)</b>	<b>(100)</b>	<b>(100)</b>
Net proceeds from shares	3,518	0	0	0	0
Net bank borrowing	(50)	0	0	0	0
Proceeds from issuance of convertible promissory notes	0	0	0	0	0
Other financing activities	(28)	0	0	0	0
<b>Net cash from financing activities</b>	<b>3,440</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
FX changes	(107)	(121)	0	0	0
<b>Net change in cash</b>	<b>3,672</b>	<b>(1,114)</b>	<b>(1,797)</b>	<b>(860)</b>	<b>(328)</b>
Cash at the beginning of the	1,193	4,759	3,524	1,726	866
<b>Cash at the end of the year</b>	<b>4,759</b>	<b>3,524</b>	<b>1,726</b>	<b>866</b>	<b>539</b>

### Balance sheet

YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E
<b>Non-current assets</b>	<b>990</b>	<b>848</b>	<b>914</b>	<b>965</b>	<b>1,004</b>
PP&E	25	46	112	163	202
Operating lease right of use assets	15	113	113	113	113
Intangible assets	120	120	120	120	120
Goodwill	163	163	163	163	163
Other non-current assets	667	407	407	407	407
<b>Current assets</b>	<b>5,344</b>	<b>4,782</b>	<b>2,924</b>	<b>2,110</b>	<b>1,912</b>
Inventories	0	27	0	7	26
Trade and bills receivables	130	33	0	39	150
Prepayments, other receivables	195	191	191	191	191
Other financial assets	259	1,007	1,007	1,007	1,007
Cash and bank balances	4,759	3,524	1,726	866	539
<b>Current liabilities</b>	<b>576</b>	<b>624</b>	<b>31</b>	<b>42</b>	<b>70</b>
Short-term borrowings	0	0	0	0	0
Advance from customers	0	0	0	0	0
Other payables and accruals	561	593	0	11	39
Operating lease liabilities, current	8	31	31	31	31
Other current liabilities	8	0	0	0	0
<b>Non-current liabilities</b>	<b>131</b>	<b>418</b>	<b>418</b>	<b>418</b>	<b>418</b>
Convertible promissory notes	0	0	0	0	0
Onshore convertible loans	6	82	82	82	82
Other non-current liabilities	125	336	336	336	336
<b>Total net assets</b>	<b>5,627</b>	<b>4,588</b>	<b>3,390</b>	<b>2,616</b>	<b>2,429</b>
Minority interest	0	0	0	0	0
<b>Shareholders' equity</b>	<b>5,627</b>	<b>4,588</b>	<b>3,390</b>	<b>2,616</b>	<b>2,429</b>

### Key ratios

YE 31 Dec	FY20A	FY21A	FY22E	FY23E	FY24E
<b>Profit &amp; loss ratios (%)</b>					
Gross margin	100	100	85	86	87
EBITDA margin	N/A	N/A	N/A	N/A	N/A
Net margin	N/A	N/A	N/A	N/A	N/A
Effective tax rate (%)	3	N/A	N/A	N/A	N/A
<b>Balance sheet ratios</b>					
Current ratio (x)	9	8	95	51	27
Trade receivables turnover	N/A	90	90	90	90
Trade payables turnover days	N/A	180	180	180	180
Total debt to asset ratio (%)	11	19	12	15	17
<b>Returns (%)</b>					
ROE	8	(51)	(35)	(30)	(8)
ROA	7	(41)	(31)	(25)	(6)
<b>Per share data</b>					
EPS (RMB)	8.07	(30.69)	(14.99)	(9.68)	(2.34)
DPS (RMB)	0	0	0	0	0
BVPS (RMB)	96.47	60.40	42.41	32.73	30.40

Source: Company data, CMBIGM estimates

# Disclosures & Disclaimers

## Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

## CMBIGM Ratings

**BUY** : Stock with potential return of over 15% over next 12 months  
**HOLD** : Stock with potential return of +15% to -10% over next 12 months  
**SELL** : Stock with potential loss of over 10% over next 12 months  
**NOT RATED** : Stock is not rated by CMBIGM

**OUTPERFORM** : Industry expected to outperform the relevant broad market benchmark over next 12 months  
**MARKET-PERFORM** : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months  
**UNDERPERFORM** : Industry expected to underperform the relevant broad market benchmark over next 12 months

## CMB International Global Markets Limited

**Address:** 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

**CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)**

## Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.